Professor Terry Rabbitts

Prof. Terry Rabbitts is a molecular biologist who trained at the MRC Laboratory of Molecular Biology (LMB) in Cambridge as a post-doc with César Milstein. He succeeded Fred Sanger as head of the LMB Division of Protein and Nucleic Acid Chemistry, jointly with Cesar Milstein, and is currently Professor of Molecular Immunology at the Institute of Cancer Research, London. His work has centred on chromosomal rearrangements in antibody and T cell receptor genes and in cancer-associated chromosomal translocations. During this work, he has pioneered a number of technologies including cDNA cloning, chimaeric antibodies, gene targeting knock-in, intracellular antibody capture and antibody-derived compounds (Abd technology), including compounds to the “undruggable” RAS. Current work focusses on developing technologies to use intracellular antibodies and derived compounds as drugs against chromosomal translocation proteins and mutant RAS, aimed at leukaemia therapy.
He is a Fellow of the Royal Society, of the Academy of Medical Sciences, of the American Association for Cancer Research Academy and an EMBO Member. He has been awarded the Colworth Medal, the CIBA Medal and the Clotten Foundation Prize in recognition for his work on chromosomal translocation genes in cancer aetiology and novel approaches to cancer drug discovery.

Terry Rabbitts contributions to biotechnology include being chairman the SAB of Cambridge Antibody Technology until its IPO, of Quadrant HealthCare and of Kymab until their commercial acquisitions, and an SAB member of Domantis until its acquisition. He was a member of the Apustcan Board until its acquisition by Avacata. He is a co-founder of Orbit Discovery and Quadrucept Bio.